Avanos Medical, INC 8-K filings

Avanos Medical, Inc. announced that its stockholders have approved the pending acquisition by affiliates of American Industrial Partners (AIP) at a special meeting.

Avanos Medical announced it has received all necessary regulatory approvals for its pending acquisition by American Industrial Partners, moving closer to closing the deal.

Avanos Medical announced first quarter 2026 financial results, showing an 8.8% increase in total net sales driven by its Specialty Nutrition Systems segment, while also noting the pending acquisition by American Industrial Partners.

Avanos Medical, Inc. has entered into a definitive agreement to be acquired by American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.272 billion.

Avanos Medical, Inc. has entered into a cooperation agreement with activist investor Bradley L. Radoff, leading to the nomination of James L. Cunniff and William P. Burke as independent directors to its Board.

Avanos Medical, Inc. reported strong fourth quarter and full-year 2025 results, exceeding full-year revenue guidance and achieving the top end of EPS guidance, driven by strategic segment growth and cost management.

Avanos Medical, Inc. presented its strategic imperatives, financial outlook, and M&A pipeline at the JP Morgan Healthcare Conference, targeting $1 billion in revenue by 2030.

Avanos Medical, Inc. announced an organizational restructuring leading to the elimination of Chief Commercial Officer and General Counsel positions, with severance and equity treatment detailed for the departing executives.

Avanos Medical reports mixed Q3 2025 results with strong Specialty Nutrition growth and a new acquisition, but a net loss, while raising full-year guidance.

Avanos Medical, Inc. announced the elimination of its Chief Commercial Officer and General Counsel positions as part of a broader organizational restructuring, effective December 1, 2025.

Avanos Medical, Inc. announced the acquisition of Nexus Medical, LLC, enhancing its critical care offerings with the proprietary TKO anti-reflux needleless connector technology.

Avanos Medical, Inc. reported a significant net loss in Q2 2025 due to a goodwill impairment charge, alongside management changes and a strategic divestiture, while maintaining its full-year financial guidance.

Avanos Medical announces a slight increase in first quarter revenue, but lowers its adjusted diluted earnings per share guidance for 2025 due to tariff impacts.

Avanos Medical, Inc. finalizes separation agreement with Michael C. Greiner, including severance, bonus, benefits, and a short-term consulting role.

Avanos Medical announces the departure of Michael Greiner, the appointment of Jason Pickett as Interim CFO and Treasurer, and related compensation adjustments.

Avanos Medical held its 2025 Annual Meeting of Stockholders on April 24, 2025, where stockholders voted on key proposals, including the election of directors and an amendment to the company's long-term incentive plan.

Avanos Medical reports the departure of Interim CEO Michael Greiner and Interim CFO Warren Machan, along with the appointment of Jason Pickett as Interim CFO and Treasurer.

Avanos Medical names David Pacitti as its new Chief Executive Officer, effective April 14, 2025, with a compensation package including a base salary, bonus potential, and significant equity awards.

Avanos Medical names David Pacitti as its new Chief Executive Officer, bringing extensive healthcare industry experience to the role.

Avanos Medical announces Q4 and full-year 2024 results, highlighting 5% organic growth in Q4 and a focus on transformation initiatives, but also reports a significant net loss due to a goodwill and intangibles impairment charge.

Avanos Medical presented its growth strategy and transformation progress at the 43rd Annual JP Morgan Healthcare Conference, highlighting its focus on enteral feeding and pain management & recovery.

Avanos Medical has formalized a consulting agreement with Warren Machan, who will serve as Interim Chief Financial Officer, outlining his compensation and responsibilities.

Avanos Medical's board has approved a new one-year program to repurchase up to $25 million of its common stock.

Avanos Medical reports a slight decrease in third-quarter sales, the retirement of its CEO, and the appointment of an interim replacement.

Avanos Medical, Inc. announced a 1.4% increase in total net sales for the second quarter of 2024, driven by strong performance in Digestive Health, while also reporting a net income of $4.3 million compared to a net loss in the same period last year.

Avanos Medical, Inc. has appointed Indrani Franchini as a new independent member of its board of directors, effective July 1, 2024.

Avanos Medical has appointed Sigfrido (Sig) Delgado as Senior Vice President, Integrated Supply Chain, to lead improvements in their global supply chain.

Avanos Medical, Inc. announced a 4.3% increase in net sales and a return to profitability in the first quarter of 2024, driven by strong performance in its Digestive Health segment.

Avanos Medical successfully held its 2024 Annual Meeting, electing directors, ratifying the appointment of Deloitte & Touche LLP as independent auditors, and approving executive compensation.

Avanos Medical reported a decrease in fourth-quarter and full-year net sales, while making progress on its transformation initiative.